Tasly Pharmaceutical Group Co., Ltd
600535
Ранг среди акций
#4771
Tasly Pharmaceutical Group Co., Ltd., a company founded in 1994 and based in... Tasly Pharmaceutical Group Co., Ltd., a company founded in 1994 and based in Tianjin, China, is actively engaged in the biological medicine, health, and medical service industries within China. Its extensive product catalog encompasses a wide range of goods, including both traditional herbal and modern chemical medicines, alongside various health supplements. The firm also supplies key pharmaceutical ingredients (APIs), concentrated herbal granules, herbal extracts, and a diverse selection of tea products. Beyond its core pharmaceutical offerings, Tasly manufactures cosmetic lines featuring items such as moisturizing lotions, facial creams, eye creams, and cleansing foams. Additionally, its consumer goods division provides daily hygiene essentials like sanitary and carefree pads, in addition to specialized soaps made with honey-propolis and pollen. The company further distributes medical equipment, including different types of massage devices like tappers and cushions, as well as circulation-enhancing machines. Tasly's market presence extends globally, with significant exports directed to the United States, Russia, and numerous countries across Europe, Africa, and other parts of Asia.
Цена акции
$2.05
Рыночная капитализация
$3.07B
Изменение (1 день)
-1.37%
Изменение (1 год)
-7.80%
Страна
CN
Торговля Tasly Pharmaceutical Group Co., Ltd (600535)
Категория
Healthcare
Прибыль Tasly Pharmaceutical Group Co., Ltd (600535)
Прибыль на 2026 TTM: 0
Согласно последним финансовым отчетам Tasly Pharmaceutical Group Co., Ltd, текущая прибыль компании составляет 0. В 2026 году компания получила прибыль 0, равна прибыли за 2026, которая составила 0. Отображаемая прибыль на этой странице — это прибыль до уплаты процентов и налогов, или просто EBIT.
История прибыли компании Tasly Pharmaceutical Group Co., Ltd с 2001 по 2026
Прибыль в конце каждого года
| Год | Прибыль | Изменить |
|---|---|---|
| 2025 | $192.27M | 31.32% |
| 2024 | $146.41M | -15.13% |
| 2023 | $172.51M | -809.84% |
| 2022 | $-24.30M | -105.67% |
| 2021 | $428.51M | 92.12% |
| 2020 | $223.04M | 16.70% |
| 2019 | $191.12M | -32.79% |
| 2018 | $284.34M | 6.54% |
| 2017 | $266.90M | 23.84% |
| 2016 | $215.52M | -22.05% |
| 2015 | $276.48M | -1.18% |
| 2014 | $279.80M | 19.89% |
| 2013 | $233.39M | 34.76% |
| 2012 | $173.19M | 38.94% |
| 2011 | $124.65M | 48.07% |
| 2010 | $84.18M | 44.00% |
| 2009 | $58.46M | 26.80% |
| 2008 | $46.10M | 49.47% |
| 2007 | $30.84M | -8.16% |
| 2006 | $33.58M | 16.86% |
| 2005 | $28.74M | 10.44% |
| 2004 | $26.02M | 22.03% |
| 2003 | $21.32M | 21.82% |
| 2002 | $17.50M | 12.42% |
| 2001 | $15.57M | 0.00% |
Прибыль схожих компаний или конкурентов
| Компания | Прибыль | Разница в прибыли | Страна |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | - |
IN
|
